Table 3.
The incremental comparison of expected life years, QALYs, costs, and ICERs for five screening strategies for heart failure in patients with type 2 diabetes of 60 years or older
| Strategy | 0 No screening |
1 EMR symptoms |
2 EMR symptoms Physical Exam |
3 EMR symptoms Physical exam NTproBNP |
4 EMR symptoms Physical exam NTproBNP ECG |
5 Echocardiography |
|---|---|---|---|---|---|---|
| Life expectancy (years) | ||||||
| Men | 14.726 | 14.742 | 14.742 | 14.742 | 14.742 | 14.742 |
| Women | 16.830 | 16.851 | 16.851 | 16.851 | 16.851 | 16.852 |
| QALY expectancy (years) | ||||||
| Men | 12.345 | 12.477 | 12.477 | 12.477 | 12.477 | 12.479 |
| Women | 14.047 | 14.215 | 14.215 | 14.216 | 14.215 | 14.217 |
| Expected costs pp (euros) | ||||||
| Men | €6795 | €7605 | €7611 | €7625 | €7642 | €7667 |
| Women | €5024 | €6086 | €6093 | €6107 | €6125 | €6152 |
| Strategy comparison | NA | 1 vs 0 | 2 vs 1 | 3 vs 1 | 4 vs 1 | 5 vs 1 |
| Additional QALYs to comparator | ||||||
| Men | NA | 0.132 | 0.000 | 0.000 | 0.000 | 0.002 |
| Women | NA | 0.168 | 0.000 | 0.000 | 0.000 | 0.002 |
| Additional costs to comparator | ||||||
| Men | NA | €810 | NA | NA | NA | €62 |
| Women | NA | €1063 | NA | NA | NA | €66 |
| ICER | ||||||
| Men | NA | €6115a | Dominated | Dominated | Dominated | €29,100 |
| Women | NA | €6318a | Dominated | Dominated | Dominated | €39,326 |
In the upper part of the table the absolute expected life-years, QALYs, and costs are given for each strategy. In the lower part, for each strategy these life-years, QALYs and costs are compared to the current optimal strategy
EMR Electronic Medical Record, ICER incremental cost-effectiveness ratio
aThis is the strategy expected to be optimal for a WTP of €20,000 per QALY